Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Common Equity (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Common Equity for 16 consecutive years, with $38.1 million as the latest value for Q1 2026.

  • Quarterly Common Equity fell 5.31% to $38.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $38.1 million through Jan 2026, down 5.31% year-over-year, with the annual reading at $51.9 million for FY2025, 87.69% up from the prior year.
  • Common Equity for Q1 2026 was $38.1 million at PharmaCyte Biotech, up from $35.2 million in the prior quarter.
  • The five-year high for Common Equity was $91.3 million in Q1 2022, with the low at $27.6 million in Q2 2024.
  • Average Common Equity over 5 years is $54.9 million, with a median of $43.6 million recorded in 2025.
  • The sharpest move saw Common Equity skyrocketed 1410.68% in 2022, then tumbled 61.97% in 2024.
  • Over 5 years, Common Equity stood at $81.0 million in 2022, then tumbled by 54.63% to $36.8 million in 2023, then increased by 18.18% to $43.5 million in 2024, then fell by 18.91% to $35.2 million in 2025, then rose by 8.17% to $38.1 million in 2026.
  • According to Business Quant data, Common Equity over the past three periods came in at $38.1 million, $35.2 million, and $43.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.